Biogen is dropping controversial Alzheimer’s drug Aduhelm
Jan 31, 2024
Biogen said it will shift its focus to a newer Alzheimer’s drug, Leqembi, which it markets in a partnership with Japan-based Eisai. Leqembi received FDA approval last year.
Is Eli Lilly using ‘granfluencers’ to raise awareness of its Alzheimer’s med?
By
Marc Iskowitz
Sep 04, 2024
Here’s why older internet celebs — granfluencers — soon might be making rounds on the Alzheimer’s drug marketing scene.
FDA advisers support new Alzheimer’s drug
Jun 11, 2024
A US Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug for Alzheimer’s outweigh its harms, which can include brain swelling and...
Legislation aims to ensure ‘fair and accurate’ Alzheimer’s treatment coverage decisions
By
Kimberly Bonvissuto
Nov 21, 2023
Federal legislation that would prevent the federal government from imposing wide-reaching coverage restrictions on Alzheimer’s treatments was reintroduced last week, providing “fair and accurate”...